Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: Shionogi Receives Contract Through BARDA's Project BioShield

ByNicholas Jacobus

April 9th 2026

Aradhana Sarin: The CFO as a Catalyst

ByMike Hollan

April 9th 2026

Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement

ByNicholas Jacobus

April 9th 2026

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

ByNicholas Jacobus

April 9th 2026

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers

ByJoshua Wyatt

April 9th 2026

Pharmaceutical Executive Digital Edition - March 2010

Articles in this issue

Newsletter

Related Content

Pharmaceutical Executive Daily: Shionogi Receives Contract Through BARDA's Project BioShield

Aradhana Sarin: The CFO as a Catalyst

Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers

Trending on PharmExec

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report

Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty

Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers